SCHEMBL6947197

SCHEMBL6947197

CCOc1ccccc1NC=C1C(=O)N(c2ccc(S(=O)(=O)N3CCOCC3)cc2)N=C1C

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.45
USP2 O75604 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HSD17B10 Q99714 1/20 0.45
MAPT P10636 1/20 0.44
HTT P42858 1/20 0.44
ALDH1A1 P00352 4/20 0.44
GAA P10253 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
GLA P06280 1/20 0.44
PTGS2 P35354 1/20 0.44
TSHR P16473 1/20 0.43
RAB9A P51151 1/20 0.43
MAPK1 P28482 1/20 0.43
CNR1 P21554 1/20 0.43
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6947196 1.00 KDM4E (0.45) KDM4EUSP2SMN1; SMN2HSD17B10MAPT
SCHEMBL8022346 0.95 PTGS2 (0.42) KDM4EUSP2SMN1; SMN2HSD17B10MAPT
SCHEMBL8423675 0.95 PTGS2 (0.42) KDM4EUSP2SMN1; SMN2HSD17B10MAPT
SCHEMBL6953284 0.93 ALDH1A1 (0.42) KDM4ESMN1; SMN2MAPTALDH1A1GAA
SCHEMBL6953281 0.93 ALDH1A1 (0.42) KDM4ESMN1; SMN2MAPTALDH1A1GAA
SCHEMBL6952740 0.92 KDM4E (0.50) KDM4EUSP2SMN1; SMN2HSD17B10MAPT
SCHEMBL6952744 0.92 KDM4E (0.50) KDM4EUSP2SMN1; SMN2HSD17B10MAPT
SCHEMBL8427590 0.89 MEN1 (0.39) KDM4ESMN1; SMN2MAPTALDH1A1GAA
SCHEMBL8427587 0.89 MEN1 (0.39) KDM4ESMN1; SMN2MAPTALDH1A1GAA
SCHEMBL6951965 0.88 KDM4E (0.43) KDM4ESMN1; SMN2HSD17B10ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0743304-B1 4-(Arylaminomethylene)-2,4-dihydro-pyrazol-3-ones MERCK PATENT GMBH (DE) 2003-03-26 EP claimed
US-6034099-A Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones CELL PATHWAYS, INC. (US) 2000-03-07 US claimed
EP-0743304-A1 4-(Arylaminomethylene)-2,4-dihydro-pyrazol-3-ones MERCK PATENT GmbH (DE) 1996-11-20 EP claimed
EP-0743304-B1 4-(Arylaminomethylene)-2,4-dihydro-pyrazol-3-ones MERCK PATENT GMBH (DE) 2003-03-26 EP disclosed
US-6034099-A Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones CELL PATHWAYS, INC. (US) 2000-03-07 US disclosed
EP-0930881-A1 PYRAZOLINONES TO TREAT DISTURBANCES OF POTENCY MERCK PATENT GmbH (DE) 1999-07-28 EP disclosed
US-5869516-A 4-(arylaminomethylene)-2,4-dihydro-3-pyrazolones MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1999-02-09 US disclosed
WO-1998016224-A1 PYRAZOLINONES TO TREAT DISTURBANCES OF POTENCY MERCK PATENT GMBH (DE) 1998-04-23 WO disclosed
EP-0743304-A1 4-(Arylaminomethylene)-2,4-dihydro-pyrazol-3-ones MERCK PATENT GmbH (DE) 1996-11-20 EP disclosed